# Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

> **NCT05533697** · PHASE1,PHASE2 · RECRUITING · sponsor: **ModernaTX, Inc.** · enrollment: 361 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **BIOLOGICAL:** mRNA-4359
- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** Ipilimumab
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT05533697
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-01
- **Primary completion:** 2032-02-18
- **Final completion:** 2032-02-18
- **Target enrollment:** 361 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05533697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05533697, "Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05533697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*